S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:JAGX

Jaguar Health (JAGX) Stock Price, News & Analysis

$0.09
+0.02 (+23.32%)
(As of 03/28/2024 ET)
Today's Range
$0.07
$0.09
50-Day Range
$0.06
$0.14
52-Week Range
$0.05
$1.22
Volume
61.88 million shs
Average Volume
79.55 million shs
Market Capitalization
$4.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Jaguar Health MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
14.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Jaguar Health in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.83) to ($0.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.11 out of 5 stars

JAGX stock logo

About Jaguar Health Stock (NASDAQ:JAGX)

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

JAGX Stock Price History

JAGX Stock News Headlines

StockNews.com Initiates Coverage on Jaguar Health (NASDAQ:JAGX)
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Jaguar Health, Inc.
Capricor Therapeutics, Inc. (4LN2.F)
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Jaguar Health Inc
Jaguar Health, Inc. (JAGX)
Jaguar Health Inc (JAGX)
Jaguar Health Inc JAGX
See More Headlines
Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/17/2021
Today
3/29/2024
Next Earnings (Confirmed)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:JAGX
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

Net Income
$-47,450,000.00
Net Margins
-370.40%
Pretax Margin
-380.79%

Debt

Sales & Book Value

Annual Sales
$11.96 million
Book Value
($0.32) per share

Miscellaneous

Free Float
50,675,000
Market Cap
$4.56 million
Optionable
No Data
Beta
1.31
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Ms. Lisa A. Conte (Age 65)
    Founder, CEO, President & Director
    Comp: $771.4k
  • Dr. Pravin R. Chaturvedi Ph.D. (Age 61)
    Chief Scientific Officer & Chair of Scientific Advisory Board
    Comp: $539.04k
  • Mr. Jonathan S. Wolin CPA (Age 61)
    J.D., M.B.A., Chief of Staff, Chief Compliance Officer & General Counsel
    Comp: $520.29k
  • Mr. Ian H. Wendt M.B.A. (Age 56)
    Chief Commercial Officer
    Comp: $441.31k
  • Dr. Steven R. King Ph.D. (Age 66)
    Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary
    Comp: $477.66k
  • Ms. Carol R. Lizak M.B.A. (Age 60)
    Chief Financial Officer
  • Mr. Peter Hodge
    Senior Director of Investor Relations, Business Development & Special Events
  • Dr. Karen J. Brunke Ph.D. (Age 71)
    Executive VP of Corporate & Business Development
  • Mr. David Sesin
    Chief Manufacturing Officer

JAGX Stock Analysis - Frequently Asked Questions

How have JAGX shares performed in 2024?

Jaguar Health's stock was trading at $0.1514 at the beginning of the year. Since then, JAGX shares have decreased by 40.6% and is now trading at $0.0899.
View the best growth stocks for 2024 here
.

When is Jaguar Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our JAGX earnings forecast
.

How can I listen to Jaguar Health's earnings call?

Jaguar Health will be holding an earnings conference call on Monday, April 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) released its quarterly earnings data on Wednesday, November, 17th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.09. The biotechnology company had revenue of $0.63 million for the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 1,191.67% and a negative net margin of 370.40%. During the same period in the prior year, the firm earned ($0.63) EPS.

When did Jaguar Health's stock split?

Jaguar Health shares reverse split on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

When did Jaguar Health IPO?

Jaguar Health (JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Who are Jaguar Health's major shareholders?

Jaguar Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Jaguar Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JAGX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners